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Abbreviations
and Acronyms
CHD = coronary heart
disease
CI = conﬁdence interval
CK = creatine kinase
HDL-C = high-density
lipoprotein cholesterol
LDL-C = low-density
lipoprotein cholesterol
LDLR = low-density
lipoprotein receptor
NCEP = National Cholesterol
Education Program
PCSK9 = proprotein
convertase subtilisin/kexin
type 9
Q2W = every 2 weeks
QM = monthly
VLDL-C = very low-density
lipoprotein cholesterol
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2542Lowering low-density lipopro-
tein cholesterol (LDL-C) with
statins reduces cardiovascular risk
(1,2). Although statins are well
tolerated, statin-related adverse
events have been reported more
commonly than in the randomized
trials, reaching up to 10% to 20%
of patients (3). Although Zhang
et al. (3) reported that a substantial
proportion of patients with side
effects to 1 statin tolerated a re-
challenge to a second statin,
failure to achieve treatment target
in patients intolerant of multiple
statins is expected to translate into
lower beneﬁts in cardiovascular
risk (1–4). The cholesterol ab-
sorption inhibitor, ezetimibe, is
well tolerated, but yields only a
minor reduction in LDL-C.
Other therapies include bile acidsequestrants and nicotinic acid, but these agents are usually
poorly tolerated. Novel potent LDL-C lowering therapies,
such as the apolipoprotein-B synthesis inhibitor and the
microsomal triglyceride transfer protein inhibitor, are
characterized bymarked side effects, limitingwider usage (5,6).
Proprotein convertase subtilisin/kexin type 9 (PCSK9)
is a protein involved in regulating low-density lipoprotein
receptor (LDLR) recycling (7–9). Evolocumab (AMG
145) is a fully human monoclonal antibody that binds to
PCSK9 and inhibits its interaction with the LDLR,
resulting in increased receptor recycling and LDL clear-
ance. In a phase 2 dose-ﬁnding study, evolocumab reduced
LDL-C in statin-intolerant patients and showed favorable
short-term tolerability (10). We now report on the
GAUSS-2 (Goal Achievement after Utilizing an Anti-
PCSK9 Antibody in Statin Intolerant Subjects-2) trial
(11), a phase 3 study that compared the effects of evolo-
cumab with ezetimibe in statin-intolerant hypercholester-
olemic patients. Compared with GAUSS, which included
patients intolerant to at least 1 statin, the present phase 3
trial evaluated evolocumab compared with ezetimibe using
a placebo-controlled design in patients intolerant to at
least 2 statins.Methods
Patients. GAUSS-2 enrolled patients aged 18 to 80 years
on no or low-dose statins. Participants had LDL-C above
their National Cholesterol Education Program (NCEP)
Adult Treatment Panel III goal (12). Participants had pre-
vious intolerance to 2 statins, deﬁned as inability to
tolerate any dose or increase the dose above the smallest
tablet strength because of intolerable muscle-related side
effects (11).Study design and oversight. The institutional review
boards approved the protocol, and all patients provided
written informed consent. GAUSS-2 was a randomized,
double-blind, phase 3, placebo- and ezetimibe-controlled
study (11). Patients were randomized 2:2:1:1 to subcu-
taneous evolocumab 140 mg every two weeks (Q2W) or
evolocumab 420 mg once monthly (QM) both with daily
oral placebo or subcutaneous placebo Q2W or QM both
with daily oral ezetimibe. Patients and all study personnel
were blinded to treatment assignment. An independent data
monitoring committee reviewed all data.
Study procedures. Study procedures were similar to those
listed in the MENDEL-2 (Anti-PCKS9 Monotherapy
for Hypercholesterolemia: The MENDEL-2 Randomized,
Controlled Phase III Clinical Trial of Evolocumab) study
(13).
Efﬁcacy and safety evaluations. Co-primary endpoints
were percent change from baseline in LDL-C at the mean of
weeks 10 and 12 and at week 12. Co-secondary efﬁcacy end-
points at the same time points included change from baseline
in LDL-C, percent of patients with LDL-C <70 mg/dl,
and percent change from baseline in non–high-density
lipoprotein cholesterol (HDL-C), apolipoprotein B, total
cholesterol/HDL-C ratio, apolipoprotein B/apolipoprotein
A-I ratio, lipoprotein(a), triglycerides, HDL-C, and very
low-density lipoprotein (VLDL-C) (10). Safety endpoints
included treatment-emergent and serious adverse events,
creatine kinase (CK) and hepatic enzyme elevations, and
anti-evolocumab antibodies.
Statistical analysis. Planned enrollment of 300 patients
(200 on evolocumab) had 92% power to detect superiority
of evolocumab regimens over ezetimibe based on a 2-sided t-
test with 0.05 signiﬁcance level for co-primary endpoints.
Statistical analyses were similar to those in the MENDEL-2
study (13).Results
Patients. Between January and August 2013, 307 patients
were randomized to evolocumab (n ¼ 205) or ezetimibe
(n ¼ 102) (Table 1, Online Table S1). Patients had a
baseline LDL-C of 193 59 mg/dl. Lipid-lowering therapy
was used by 33% of patients; 18% received a low-dose statin.
Fifty-six percent of patients were at high risk of coronary
heart disease (CHD) according to the NCEP. Treatment
was completed by 96% of patients on evolocumab and 86%
of patients on ezetimibe. Eight patients discontinued evo-
locumab (4%) for adverse events (n ¼ 6), patient request
(n ¼ 1), or loss to follow-up (n ¼ 1). Fourteen patients
discontinued ezetimibe (14%) for adverse events (n ¼ 11),
patient request (n ¼ 2), or other reason (n ¼ 1). The study
was completed by 290 patients (94%) (Online Fig. S1).
Efﬁcacy outcomes. LOW-DENSITY LIPOPROTEIN CHOLESTEROL.
Evolocumab yielded signiﬁcant reductions in LDL-C
(Table 2). Mean percent reductions from baseline at a mean
of weeks 10 and 12 were 56.1% (95% conﬁdence interval
Table 1 Baseline Characteristics
Ezetimibe QD þ
PBO Q2W
(n ¼ 51)
Evolocumab 140 mg Q2W þ
PBO QD
(n ¼ 103)
Ezetimibe QD þ
PBO QM
(n ¼ 51)
Evolocumab 420 mg QM þ
PBO QD
(n ¼ 102)
Age, yrs 62  10 61  10 60  9 63  10
Male 24 (47) 57 (55) 29 (57) 56 (55)
Race
White 49 (96) 94 (91) 46 (90) 98 (96)
Black 0 3 (3) 1 (2) 3 (3)
Lipid parameters
LDL-C, mg/dl 195  64 192  57 195  52 192  61
Apolipoprotein B, mg/dl 140  37 140  32 140  31 133  32
Lipoprotein(a), nmol/l 57 (22, 205) 39 (10, 101) 26 (7, 181) 31 (9, 80)
Apolipoprotein A-I, mg/dl 154  34 149  29 144  23 153  24
HDL-C, mg/dl 52  18 51  16 48  11 54  16
Free PCSK9, ng/ml 317  125 285  80 295  98 266  95
Statin-related history
No. of intolerable statins
2 25 (49) 46 (45) 17 (33) 50 (49)
3 13 (26) 37 (36) 22 (43) 32 (31)
4 13 (25) 20 (19) 12 (24) 20 (20)
Worst muscle-related side effect*
Myalgia 40 (78) 80 (78) 45 (88) 81 (79)
Myositis 11 (22) 20 (19) 4 (8) 19 (19)
Rhabdomyolysis 0 2 (2) 2 (4) 2 (2)
Lipid-lowering therapy at baseline
Any 15 (29) 34 (33) 16 (31) 37 (36)
Rosuvastatin 6 (12) 10 (10) 2 (4) 9 (9)
Simvastatin 0 1 (1) 3 (6) 3 (3)
Atorvastatin 1 (2) 1 (1) 2 (4) 2 (2)
Other statin 2 (4) 7 (7) 3 (6) 3 (3)
Cardiovascular risk factors
Current cigarette use 5 (10) 12 (12) 4 (8) 3 (3)
Type 2 diabetes mellitus 11 (22) 20 (19) 16 (31) 15 (15)
Hypertension 30 (59) 57 (55) 38 (75) 56 (55)
Family history of premature CHDy 10 (20) 31 (30) 22 (43) 36 (35)
Low HDL-Cz 18 (35) 37 (36) 18 (35) 29 (28)
2 CV risk factors 20 (39) 54 (52) 35 (69) 38 (37)
NCEP risk categoriesx
High 32 (63) 51 (50) 32 (63) 58 (57)
Moderately high 5 (10) 16 (16) 8 (16) 16 (16)
Moderate 9 (18) 20 (19) 8 (16) 16 (16)
Lower 5 (10) 16 (16) 3 (6) 12 (12)
Values are mean  SD or n (%), unless otherwise noted. *Data are missing for 1 patient in the evolocumab Q2W arm; myalgia, muscle symptoms without creatine kinase (CK) elevation; myositis, muscle
symptoms with CK elevation; rhabdomyolysis, muscle symptoms with marked CK elevation. yCHD in male ﬁrst-degree relative at <55 years of age or in female ﬁrst-degree relative at <65 years of age.
zDeﬁned as <40 mg/dl in men and <50 mg/dl in women. xRisk category deﬁnitions: high (diagnosed CHD or risk equivalent); moderately high (2 or more risk factors and Framingham risk score 10% to
20%); moderate (2 or more risk factors and Framingham risk score <10%); and lower (0 or 1 risk factor).
CHD ¼ coronary heart disease; CV ¼ cardiovascular; HDL-C ¼ high-density lipoprotein cholesterol; IQR ¼ interquartile range; LDL-C ¼ low-density lipoprotein cholesterol; NCEP ¼ National Cholesterol
Education Program; PBO ¼ placebo; PCSK9 ¼ proprotein convertase subtilisin/kexin type 9; Q2W ¼ every 2 weeks; QD ¼ daily; QM, ¼ monthly.
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2543[CI]: 59.7% to 52.5%) with 140 mg Q2W and 55.3% (95%
CI: 58.3% to 52.3%) with 420 mg QM, corresponding to
treatment differences versus ezetimibe of 36.9% (95% CI:
42.3% to 31.6%) and 38.7% (95% CI: 43.1% to 34.3%),
respectively (p <0.001). Mean percent reductions from baseline
and treatment differences at week 12 were similar (p < 0.001).
Reductions in LDL-C were sustained throughout the trial (Fig
1). Evolocumab-treated patients were more likely to achieve
LDL-C target levels than ezetimibe-treated patients (Fig. 2).OTHER LIPIDS. Compared with ezetimibe, evolocumab led
to signiﬁcant reductions in apolipoprotein B, lipoprotein(a),
non–HDL-C, and the apolipoprotein B/apolipoprotein A-I
and total cholesterol/HDL-C ratios (p < 0.001) (Table 2,
Online Table S2).
Safety outcomes. Treatment-emergent adverse events are
listed in Table 3 and the Online Appendix. Adverse events
led to study drug discontinuation in 8% (evolocumab) and
13% (ezetimibe) of patients. Myalgia occurred in 8% of
Table 2 Efﬁcacy Outcomes
Ezetimibe QD þ
PBO Q2W
(n ¼ 51)
Evolocumab 140 mg Q2W þ
PBO QD
(n ¼ 103)
Ezetimibe QD þ
PBO QM
(n ¼ 51)
Evolocumab 420 mg QM þ
PBO QD
(n ¼ 102)
LDL-C, %
% change from baseline, mean of
weeks 10 and 12*
–19.2 (–23.9, –14.5) –56.1 (–59.7, –52.5) –16.6 (–20.6, –12.6) –55.3 (–58.3, –52.3)
Treatment difference vs. ezetimibey –36.9 (–42.3, –31.6) –38.7 (–43.1, –34.3)
% change from baseline, week 12* –18.1 (–23.1, –13.1) –56.1 (–59.9, –52.4) –15.1 (–19.3, –10.9) –52.6 (–55.7, –49.5)
Treatment difference vs. ezetimibey –38.1 (–43.7, –32.4) –37.6 (–42.2, –32.9)
LDL-C, mg/dl
Change from baseline, mean of
weeks 10 and 12, mg/dl
–39.1 (–49.3, –29.0) –105.4 (–113.1, –97.7) –33.0 (–41.9, –24.1) –103.6 (–110.2, –96.9)
Treatment difference vs. ezetimibey –66.3 (–77.9, –54.7) –70.6 (–80.5, –60.7)
Change from baseline, week 12, mg/dl –36.2 (–46.9, –25.5) –106.0 (–114.0, –97.9) –30.2 (–39.5, –20.9) –99.0 (–105.9, –92.1)
Treatment difference vs. ezetimibey –69.7 (–82.0, –57.5) –68.8 (–79.2, –58.4)
Other lipid parameters
Apolipoprotein B
% change from baseline, mean of
weeks 10 and 12
–13.7 (–17.9, –9.4) –45.9 (–49.2, –42.6) –11.0 (–15.4, –6.7) –46.0 (–49.3, –42.7)
Treatment difference vs. ezetimibey –32.2 (–36.9, –27.5) –35.0 (–39.6, –30.4)
% change from baseline, week 12 –13.0 (–17.5, –8.4) –45.8 (–49.4, –42.3) –10.0 (–14.6, –5.4) –43.1 (–46.5, –39.7)
Treatment difference vs. ezetimibey –32.9 (–38.0, –27.7) –33.1 (–38.0, –28.2)
Lipoprotein(a)
% change from baseline, mean of
weeks 10 and 12
–2.3 (–8.9, 4.3) –26.2 (–31.4, –21.0) 1.6 (–6.4, 9.5) –23.7 (–29.6, –17.9)
Treatment difference vs. ezetimibey –23.9 (–31.3, –16.5) –25.3 (–33.8, –16.8)
% change from baseline, week 12 –1.7 (–8.8, 5.3) –27.0 (–32.5, –21.5) 5.8 (–4.3, 15.9) –22.1 (–29.3, –14.8)
Treatment difference vs. ezetimibey –25.3 (–33.3, –17.3) –27.9 (–39.2, –16.6)
HDL-C
% change from baseline, mean of
weeks 10 and 12
0.3 (–3.6, 4.2) 5.5 (2.5, 8.5) 1.4 (–2.6, 5.5) 7.2 (4.2, 10.2)
Treatment difference vs. ezetimibe 5.2 (0.7, 9.6) 5.7 (1.2, 10.2)
% change from baseline, week 12 1.8 (–2.6, 6.2) 5.3 (2.0, 8.6) 1.6 (–2.7, 6.0) 6.5 (3.3, 9.7)
Treatment difference vs. ezetimibe 3.6 (–1.5, 8.6) 4.8 (–0.2, 9.8)
Apolipoprotein A-I
% change from baseline, mean of
weeks 10 and 12
–0.1 (–3.4, 3.3) 5.4 (2.7, 8.1) 2.6 (–1.1, 6.2) 5.3 (2.5, 8.0)
Treatment difference vs. ezetimibe 5.5 (1.7, 9.2) 2.7 (–1.2, 6.5)
% change from baseline, week 12 1.1 (–2.4, 4.6) 5.2 (2.4, 7.9) 3.2 (–0.9, 7.2) 5.5 (2.5, 8.5)
Treatment difference vs. ezetimibe 4.1 (0.1, 8.0) 2.3 (–2.1, 6.8)
LDL-C achievement <70 mg/dl
Mean of weeks 10 and 12 1 (2.0) 46 (45.5) 0 42 (42.0)
Treatment difference vs. ezetimibe,y % 43.5 (30.9, 53.4) 42.0 (30.3, 51.8)
Week 12 1 (2.0) 49 (50.0) 0 36 (37.5)
Treatment difference vs. ezetimibe,y % 48.0 (35.0, 57.8) 37.5 (25.5, 47.5)
PCSK9
% change from baseline, week 10 –6.4  38.4 –61.8  31.2 7.9  61.9 –93.9  17.0
% change from baseline, week 12 1.1  30.0 –61.1  33.8 0.7  60.0 –27.2  163.9
Values are mean  SD or least squares mean (95% conﬁdence interval) unless otherwise speciﬁed. Least squares mean is from the repeated measures model, including covariates of stratiﬁcation factors,
treatment group, scheduled visit, and interaction of treatment with scheduled visits. *Co-primary endpoint. yAdjusted p value versus ezetimibe <0.001; multiplicity adjustments within each dose frequency
were used to control for the overall signiﬁcance level for all primary and secondary endpoints.
Abbreviations as in Table 1.
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2544evolocumab-treated patients and 18% of ezetimibe-treated
patients. Patients using low-dose statin therapy were more
likely to develop myalgia in the ezetimibe (statin vs. no statin:
21% vs. 17%) and the evolocumab group (statin vs. no statin:
17% vs 6%). Discontinuation rates due to musculoskeletal side
effects were 5% (evolocumab) and 6% (ezetimibe). No bind-
ing or neutralizing antibodies to evolocumab were detected.Discussion
In the GAUSS-2 study, evolocumab administered over
3 months yielded a signiﬁcant reduction in LDL-C in hy-
percholesterolemic patients who were unable to tolerate
effective doses of at least 2 statins, reﬂecting a population
with a true unmet need.
Figure 1
Mean Percent Change in Low-Density Lipoprotein Cholesterol Concentration from Baseline to Week 12 in Patients
Who Received Evolocumab
Patients who received evolocumab (A) every 2 weeks and (B) monthly. Vertical lines represent SE around the mean. No imputation was used for missing data; the plot
is based on observed values. BL ¼ baseline; LDL-C ¼ low-density lipoprotein cholesterol; Q2W ¼ every 2 weeks; QM ¼ monthly; SC ¼ subcutaneous.
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2545Evolocumab treatment resulted in a 53% to 56% reduc-
tion in LDL-C, with comparable reductions between dosing
regimens. In GAUSS-2, 82% of patients used no statin,
leading to markedly elevated LDL-C levels (mean of 193
mg/dl) comparable to those observed in early secondary
prevention trials (14). Of evolocumab-treated patients at
high risk, more than 75% achieved LDL-C <100 mg/dl
compared with less than 10% of ezetimibe-treated patients.
In the context of the American College of Cardiology/
American Heart Association guidelines (15), these ﬁndings
imply that evolocumab could be a promising alternative
agent to lower LDL-C in statin-intolerant patients with
markedly elevated LDL-C levels.
Compared with the dose-ﬁnding phase 2 trial (GAUSS)
(10), GAUSS-2 enrolled a population at a higher cardio-
vascular risk, with more patients intolerant of at least 2
statins, leading to the inclusion of patients with a truly
unmet clinical need. In the upcoming results of the outcome
trial with evolocumab (Further Cardiovascular Outcomes
Research With PCSK9 Inhibition in Subjects with ElevatedRisk; NCT01764633), the observed 100 mg/dl reduction
in LDL-C can be expected to reduce cardiovascular risk,
given the 22% risk reduction per 39 mg/dl LDL-C decrease
reported for statins (1,2).
In GAUSS-2, ezetimibe was selected as comparator based
on its favorable tolerability and widespread use in statin-
intolerant patients (16). The majority of patients using
ezetimibe were unable to achieve LDL-C target levels, as
evidenced by the 2% rate of achieving LDL-C <70 mg/dl.
Moreover, beneﬁt of ezetimibe-induced, LDL-C lowering
awaits conﬁrmation in the ongoing outcome study
(IMPROVE-IT [Improved Reduction of Outcomes:
Vytorin Efﬁcacy International Trial]; NCT00202878) (17).
Evolocumab also reduced lipoprotein(a) levels by 27%
(Q2W) and 22% (QM) at week 12, consistent with lip-
oprotein(a) reductions reported in previous studies using
PCSK9-targeting programs (18–20). Further studies on the
mechanism of lipoprotein(a) lowering and the beneﬁt of
evolocumab in patients with elevated lipoprotein(a) levels are
warranted.
Figure 2
Percentage of Patients Achieving Low-Density Lipoprotein Cholesterol Goal at Week 12 and at Mean of Weeks 10 and 12
Stratiﬁed by National Cholesterol Education Program Risk Category
Rates based on patients with observed values and LDL-C above target goal at baseline. National Cholesterol Education Program (NCEP) risk categories are deﬁned as high
(diagnosed coronary heart disease or risk equivalent), moderately high (2 or more risk factors and Framingham risk score 20%), and lower (0 or 1 risk factor). PBO ¼ placebo;
other abbreviations as in Figure 1.
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2546Evolocumab was well tolerated with 96% of patients
completing treatment. With all patients having historically
experienced muscle-related side effects during statin ther-
apy, myalgia incidence was low (18%, 7%, and 9% of
patients in the ezetimibe, evolocumab Q2W, and evolo-
cumab QM groups, respectively). In the MENDEL-2
study (13), these rates were 1%, 1%, and 1%, respectively.
Notwithstanding the higher rate in statin-intolerant pa-
tients, there was no increase in muscle-related side effects in
the evolocumab- compared with ezetimibe-treated patients.
This suggests that the pathways contributing to statin-
associated myalgia and/or myositis (21,22) are distinct from
those contributing to PCSK9 antibody-mediated LDL-C
lowering. Because the study was short term, these data await
conﬁrmation in the FOURIER (Further CardiovascularOutcomes Research With PCSK9 Inhibition in Subjects
With Elevated Risk; NCT01764633) outcome study.
The incidence of treatment-emergent adverse events and
laboratory abnormalities were comparable across treatment
groups.
Study limitations. A limitation of this study includes
the absence of a blinded statin re-challenge. We used a
real-life deﬁnition of patients who experienced intolera-
ble muscle-related side effects to 2 statins, with the ma-
jority unable to tolerate 3 statins. A placebo-controlled
blinded statin re-challenge has, however, been included in
the GAUSS-3 (Goal Achievement After Utilizing an
Anti-PCSK9 Antibody in Statin Intolerant Subjects-3;
NCT01984424) study. Another limitation is the short
study duration in patients needing life-long treatment;
Table 3 Adverse Events
Event
Ezetimibe Evolocumab
QD þ PBO Q2W
(n ¼ 51)
QD þ PBO QM
(n ¼ 51)
All
(N ¼ 102)
140 mg Q2W þ PBO QD
(n ¼ 103)
420 mg QM þ PBO QD
(n ¼ 102)
All
(N ¼ 205)
Treatment emergent
Any 35 (69) 39 (77) 74 (73) 63 (61) 72 (71) 135 (66)
Serious 1 (2) 3 (6) 4 (4)* 5 (5) 1 (1) 6 (3)y
Leading to discontinuation of
investigational product
4 (8) 9 (18) 13 (13) 6 (6) 11 (11) 17 (8)
Deaths 0 0 0 0 0 0
Common treatment emergentz
Headache 3 (6) 6 (12) 9 (9) 4 (4) 12 (12) 16 (8)
Myalgia 7 (14) 11 (22) 18 (18) 7 (7) 9 (9) 16 (8)
Pain in extremity 0 1 (2) 1 (1) 2 (2) 12 (12) 14 (7)
Muscle spasms 3 (6) 1 (2) 4 (4) 5 (5) 8 (8) 13 (6)
Fatigue 4 (8) 6 (12) 10 (10) 3.(3) 6 (6) 9 (4)
Nausea 2 (4) 5 (10) 7 (7) 3 (3) 6 (6) 9 (4)
Nasopharyngitis 3 (6) 0 3 (3) 5 (5) 2 (2) 7 (3)
Diarrhea 3 (6) 4 (8) 7 (7) 3 (3) 2 (2) 5 (2)
Injection site erythema 0 3 (6) 3 (3) 2 (2) 2 (2) 4 (2)
Paraesthesia 1 (2) 4 (8) 5 (5) 0 2 (2) 2 (1)
Inﬂuenza 3 (6) 0 3 (3) 1 (1) 0 1 (<1)
Pruritus 1 (2) 3 (6) 4 (4) 0 0 0
Abnormal laboratory tests
CK >5  ULN 3 (6) 0 3 (3) 0 2 (2) 2 (1)
CK >10  ULN 1 (2) 0 1 (1) 0 0 0
ALT or AST >3  ULN 0 0 0 0 0 0
Muscle-related SMQ 8 (16) 15 (29) 23 (23) 13 (13) 12 (12) 25 (12)
Myositis 0 0 0 0 1 (1) 1 (<1)
Myalgia 7 (14) 11 (22) 18 (18) 7 (7) 9 (9) 16 (8)
Musculoskeletal pain 1 (2) 2 (4) 3 (3) 1 (1) 2 (2) 3 (2)
Muscular weakness 0 1 (2) 1 (1) 2 (2) 0 2 (1)
Increased plasma creatinine 0 0 0 2 (2) 0 2 (1)
Blood CK increased 0 1 (2) 1 (1) 2 (2) 0 2 (1)
Potential injection site reactionsx 1 (2) 7 (14) 8 (8) 3 (3) 3 (3) 6 (3)k
Anti-evolocumab antibodies
Binding NA NA NA 0 0{ 0
Neutralizing NA NA NA 0 0{ 0
Neurocognitive adverse events# 0 0 0 0 0 0
Values are n (%). *Gastrointestinal motility disorder (n ¼ 1), inguinal hernia (n ¼ 1), kidney infection (n ¼ 1), spinal decompression (n ¼ 1). yIncreased hepatic enzymes (n ¼ 1), back pain (n ¼ 1), carcinoma
(n ¼ 2; bladder and neuroendocrine), lipoma (n ¼ 1), and musculoskeletal surgery (n ¼ 1). zReported in 5% of patients in 1 or more treatment arms. xSearched using high-level term grouping, which
includes injection site (IS) rash, IS inﬂammation, IS pruritus, IS reaction, and IS urticaria. kReactions consisted of erythema (n ¼ 4), pain (n ¼ 3), rash (n ¼ 2), bruising, irritation, swelling, and urticaria (n ¼ 1
each). {Data missing for 1 patient. #Searched using HLGT terms: deliria (including confusion); cognitive and attention disorders and disturbances; dementia and amnestic conditions; disturbances in thinking
and perception; mental impairment disorders.
ALT ¼ alanine aminotransferase; AST ¼ aspartate aminotransferase; CK ¼ creatine kinase; NA ¼ not applicable; SMQ ¼ Standard MedDRA Queries; ULN ¼ upper limit of normal; other abbreviations as in
Table 1.
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extension study (Open Label Study of Long Term Evalua-
tion Against LDL-C Trial-2; NCT01854918) following
GAUSS-2.Conclusions
Evolocumab treatment yielded a robust reduction in
plasma LDL-C in hypercholesterolemic patients with statin
intolerance. The low incidence of muscle-related side
effects in GAUSS-2 underscores evolocumab as a useful
therapy for hypercholesterolemic patients who presently
have few tolerable treatment options, provided that beneﬁtis conﬁrmed in the ongoing endpoint trial (FOURIER;
NCT01764633).
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